Her2-targeted dendritic cell vaccine shows promise for the treatment of early-stage cancer of the breast patients


Deregulation and inhibition from the defense mechanisms plays a role in cancer development. Many therapeutic strategies try to restimulate the defense mechanisms to acknowledge cancer cells and target them for destruction. Researchers from Moffitt Cancer Center are convinced that a dendritic cell vaccine that targets the HER2 protein on cancer of the breast cells is protected and effectively energizes the defense mechanisms resulting in regression of early-stage cancer of the breast.

The HER2 proteins are overexpressed in 20-25% of cancer of the breast tumors and it is connected with aggressive disease and poor prognosis. Moffitt scientific study has formerly proven that immune cells are less in a position to recognize and target cancer cells that express HER2 as cancer of the breast progresses right into a more complex and invasive stage. This means that strategies that may restimulate the defense mechanisms to acknowledge and target HER2 early during cancer development might be effective treatments.

The Moffitt researchers formerly created a vaccine that can help the defense mechanisms recognize the HER2 protein on cancer of the breast cells. Their approach involves allowing the vaccine from immune cells known as dendritic cells which are harvested from every individual patient to produce a personalized vaccine.

To be able to determine whether the HER2-dendritic cell vaccine is effective and safe, the Moffitt researchers performed a medical trial in 54 ladies who have HER2-expressing early-stage cancer of the breast. The dendritic cell vaccines were made by isolating dendritic cells from each patients’ bloodstream and exposing these to fragments from the HER2 protein. Patients were injected having a dose of the personal dendritic cell vaccine once per week for six days into whether lymph node, the breast tumor, or into both sites.

Resourse: http://news-medical.internet/news/20170103/

HER2-Targeted Therapy in Early Stage HER2+ Breast Cancer